Please login to the form below

Not currently logged in
Email:
Password:

myelodysplastic syndromes

This page shows the latest myelodysplastic syndromes news and features for those working in and with pharma, biotech and healthcare.

FDA halts third Merck myeloma trial after patient deaths

FDA halts third Merck myeloma trial after patient deaths

Revlimid is also used to treated myelodysplastic syndromes and mantle cell lymphoma.

Latest news

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    Under the terms of the deal, Celgene has the rights to develop the product for non-Hodgkin lymphoma (NHL), myelodysplastic syndromes and multiple myeloma.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

  • Pharma deals during September 2012 Pharma deals during September 2012

    Estybon is in phase III for the treatment of myelodysplastic syndromes (MDS) (rare haematologic malignancies) and in phase II/III for pancreatic cancer. ... 638. Onconova Therapeutics / Baxter International. Licence (2). Estybon (rigosertif) for

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics